BIO-PATH HOLDINGS, INC.
Close on Oct 19, 2026
- Market cap
- $2.80K
- P/E (TTM)
- –
- Dividend yield
- –
About Bio-Path
Pharmaceutical Preparations, SIC 2834
Bio-Path Holdings, Inc. is a clinical and preclinical stage biotechnology company focused on developing RNAi nanoparticle therapies for oncology and metabolic conditions. The company utilizes its proprietary DNAbilize drug delivery and antisense platform, which incorporates a modified P-ethoxy DNA backbone within a neutral lipid bilayer to target disease-causing proteins. Its drug pipeline includes prexigebersen (BP1001), under investigation in combination regimens for acute myeloid leukemia; BP1002, targeting Bcl-2 for blood cancers; BP1003, targeting STAT3 for solid tumors including pancreatic cancer; and BP1001-A, being evaluated for solid tumors as well as obesity and Type 2 diabetes. The company's technology is directed toward partnering and licensing opportunities across systemic diseases.
The company conducts clinical trials across multiple medical research institutions and cancer centers in the United States, with plans under evaluation to expand Stage 2 of its Phase 2 clinical trials into Europe. The provided text does not disclose the location of the company's corporate headquarters.
Summary of the business section of Bio-Path's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BIO-PATH HOLDINGS, INC.
- Headquarters
- Bellaire, TX
- Address
- 4710 Bellaire Boulevard, Suite 210 77401
- Phone
- (832) 742-1357
- Employees
- 10, Dec 31, 2024
- Industry
- Pharmaceutical Preparations
- Incorporated in
- WY
- Fiscal year ends
- December 31
- Auditor
- Ernst& Young, Houston, Texas
Stock & identifiers
- Ticker
- BPTH
- Exchange
- OTC
- Shares outstanding
- 50M, May 20, 2026
- Public float
- $5.04M, Jun 30, 2024
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Feb 23, 2024; 1-for-20 reverse, Feb 22, 2024; 1-for-20 reverse, Jan 18, 2019; 1-for-20 reverse, Jan 17, 2019; 1-for-10 reverse, Apr 2, 2018; 1-for-10 reverse, Feb 9, 2018
- SEC CIK
- 1133818
- EIN
- 87-0652870
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Bio-Path's leadership is listed in its proxy statement, last filed Oct 28, 2024.
Employees
Headcount reported in annual reports
“We currently employ ten full-time employees.”
Corporate history
Events identified from SEC filings